Valeant 4th Quarter results

Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results
http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-reports-fourth-quarter-and-full-year-2014-financial-results-300039434.html

Total revenue $2.3 billion ; an increase of 10% over the prior year despite negative foreign exchange impact of $113 million
Total Same Store Sales organic growth was 16%
Bausch + Lomb organic growth was 8%
Gain of $287 million , net of fees and out-of-pocket expenses, from Allergan investment, is excluded from Cash EPS and Adjusted Operating Cash Flow
GAAP EPS $1.56 ; Cash EPS $2.58 (excluding Allergan gain), an increase of 20% despite negative foreign exchange impact of $0.15 versus the prior year
GAAP Operating Cash Flow $816 million ; Adjusted Operating Cash Flow $624 million (excluding Allergan gain)
Restructuring, integration and other acquisition related costs were down to $47 million in the fourth quarter 2014
Net debt reduced to $15.3 billion , with net leverage ratio approximately 3.5 times adjusted pro forma EBITDA

 

Q1 soon

 

How soon?